Fig. 4From: A network meta-analysis of efficacy and safety for first-line and second/further-line therapies in postmenopausal women with hormone receptor-positive, HER2-negative, advanced breast cancerLife-year results within 10 years for second/further-line therapies’ PFS and OS. Abbreviations: Abema, Abemaciclib; ALP, Alpelisib; CAP, Capivasertib; ENT, Entinostat; EVE, Everolimus; EXE, Exemestane; FUL, Fulvestrant; Palbo, Palbociclib; Ribo, RibociclibBack to article page